Clinical Study Of "FuZhengKangAi" Decoction Combined With Gefitinib In Treatment Of Refractory Advanced NSCLC

Objective To evaluate the efficacy and toxicity of "FuZhengKangAi" decoction combined with Gefitinib in treatment of refractory advanced NSCLCMethodsFrom Mar2009to Sep2011,35patients with IIIB-IV NSCLC who were EGFR wild-type or had clinical factors associated with lower incidence of EGFR mutations(smokers or non-adenocarcinoma histology) in Guangdong Province Traditional Chinese Medical Hospital were eligible. All patients had refused treatment of chemotherapy. In this study, patients were treated with "FuZhengKangAi" decoction250ml/d combined with Gefitinib250mg/d until disease progression, unacceptable toxicity or withdrawal of consent. Chest CT was performed before treatment and every6weeks after treatment for cancer assessment. The objective response rate(ORR), disease control rate(DCR), progression-free survival (PFS).overall survival(OS),1-year survival rate and adverse effect were analyzed.ResultsOf the35patients,10(28.6%) were known as EGFR wild-type. At the end of follow-up on the1st Feb2012,32(91.4%) had disease progression,27(77.1%) died of lung cancer.32(91.4%) can be evaluated efficacy, in which the ORR was15.6%and the DCR was59.4%. The median Progression-free survival (PFS) was4.9(95%CI4.0-5.9) months, the median overall survival (OS) was10.9(95%CI3.7-18.0) months, and the1-year survival rate was47.0%. During the study,20(57.1%) patients were recorded of adverse reaction. The toxicity was I II rank rash (54.3%) and diarrhea(5.7%).No patient discontinued treatment due to toxicity. ConclusionThe "FuZhengKangAi " decoction combined with Gefitinib in the refractory advanced NSCLC patients who were EGFR wild-type or had clinical factors associated with lower incidence of EGFR mutations (smokers or non-adenocarcinoma histology) had better efficacy and lower toxicity, the therapy method was worthy to be popularized.